Strategic biomarker testing in upper GI and hepatobiliary cancers can guide standard-of-care treatment paradigms and are essential for the optimization of targeted therapies, but there are challenges with incorporating them in the community setting.
Doctors Vamsi Velcheti, Sandip Patel, and Michael Zervos discuss recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of neoadjuvant and adjuvant treatment options for patients and the role of surgery in the era of targeted therapy and immuno-oncology in lung cancer.
Early administration ide-cel in relapsed/refractory multiple myeloma is crucial for achieving deeper responses and should not be delayed; however, logistics and product availability remain critical components.
The genomic landscape of PanNENs has been better characterized over the last decade thanks to NGS, helping clinicians distinguish between PanNECs and PanNETs. Although the incorporation of NGS into clinical practice has been unsatisfying in PanNETs, there is great potential for the use of genomic markers in this disease process.
The early closure of the COBRA trial, which evaluated ctDNA-guided adjuvant therapy in resected stage IIA colon cancer, raises fundamental questions about ctDNA biology, the robustness of ctDNA assays, and how best to incorporate ctDNA testing in the clinic.
In light of the financial and toxicity burdens of tandem transplant in pediatric high-risk neuroblastoma, an Education Session will discuss alternative treatment options for this disease state, including ongoing clinical trials investigating incorporating immunotherapy, as well as non-transplant-contained regimens.
The 2024 ASCO Annual Meeting will be held from May 31 to June 4, at McCormick Place in Chicago, as well as online. Learn how to navigate the Windy City with these expert tips.
Idecabtagene Vicleucel in Early Relapsed/Refractory Myeloma: Is There an Efficacy Benefit?
Harnessing the Potential of Next-Generation Sequencing in Pancreatic Neuroendocrine Tumors
Closure of COBRA Trial Creates Uncertainty for ctDNA-Guided Adjuvant Therapy in Stage II Colon Cancer